Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

GH therapy and cancer risk in hypopituitarism: what we know from human studies.

Pekic S, Popovic V.

Eur J Endocrinol. 2013 Oct 1;169(5):R89-97. doi: 10.1530/EJE-13-0389. Print 2013 Nov. Review.

2.

Serum insulin-like growth factor I (IGF-I), IGF-binding proteins 2 and 3, and the risk for development of malignancies in adults with growth hormone (GH) deficiency treated with GH: data from KIMS (Pfizer International Metabolic Database).

Popovic V, Mattsson AF, Gaillard RC, Wilton P, Koltowska-Häggström M, Ranke MB.

J Clin Endocrinol Metab. 2010 Sep;95(9):4449-54. doi: 10.1210/jc.2010-0287. Epub 2010 Jul 7.

PMID:
20610598
3.

GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety.

Abs R, Bengtsson BA, Hernberg-Stâhl E, Monson JP, Tauber JP, Wilton P, Wüster C.

Clin Endocrinol (Oxf). 1999 Jun;50(6):703-13.

PMID:
10468941
4.

Fractures in pituitary adenoma patients from the Dutch National Registry of Growth Hormone Treatment in Adults.

van Varsseveld NC, van Bunderen CC, Franken AA, Koppeschaar HP, van der Lely AJ, Drent ML.

Pituitary. 2016 Aug;19(4):381-90. doi: 10.1007/s11102-016-0716-3.

5.

The value of IGF1 estimation in adults with GH deficiency.

Mukherjee A, Shalet SM.

Eur J Endocrinol. 2009 Nov;161 Suppl 1:S33-9. doi: 10.1530/EJE-09-0247. Epub 2009 Aug 14.

6.

Incidence of primary cancers and intracranial tumour recurrences in GH-treated and untreated adult hypopituitary patients: analyses from the Hypopituitary Control and Complications Study.

Child CJ, Conroy D, Zimmermann AG, Woodmansee WW, Erfurth EM, Robison LL.

Eur J Endocrinol. 2015 Jun;172(6):779-90. doi: 10.1530/EJE-14-1123. Epub 2015 Mar 25.

7.

Aspects of growth hormone deficiency and replacement in elderly hypopituitary adults.

Feldt-Rasmussen U, Wilton P, Jonsson P; KIMS Study Group; KIMS International Board.

Growth Horm IGF Res. 2004 Jun;14 Suppl A:S51-8.

PMID:
15135778
8.

Assessment of primary cancers in GH-treated adult hypopituitary patients: an analysis from the Hypopituitary Control and Complications Study.

Child CJ, Zimmermann AG, Woodmansee WW, Green DM, Li JJ, Jung H, Erfurth EM, Robison LL; HypoCCS International Advisory Board.

Eur J Endocrinol. 2011 Aug;165(2):217-23. doi: 10.1530/EJE-11-0286. Epub 2011 Jun 6.

9.

Safety of growth hormone replacement therapy in adults.

Gibney J, Johannsson G.

Expert Opin Drug Saf. 2004 Jul;3(4):305-16. Review.

PMID:
15268648
10.

Effects of 18-month of growth hormone (GH) replacement therapy in patients with Sheehan's syndrome.

Tanriverdi F, Unluhizarci K, Kula M, Guven M, Bayram F, Kelestimur F.

Growth Horm IGF Res. 2005 Jun;15(3):231-7.

PMID:
15921942
11.

Does the GH-IGF axis play a role in cancer pathogenesis?

Cohen P, Clemmons DR, Rosenfeld RG.

Growth Horm IGF Res. 2000 Dec;10(6):297-305. Review.

PMID:
11161960
12.

Does growth hormone cause cancer?

Jenkins PJ, Mukherjee A, Shalet SM.

Clin Endocrinol (Oxf). 2006 Feb;64(2):115-21. Review.

PMID:
16430706
13.

Cardiovascular risk factors in hypopituitary GH-deficient adults.

Verhelst J, Abs R.

Eur J Endocrinol. 2009 Nov;161 Suppl 1:S41-9. doi: 10.1530/EJE-09-0291. Epub 2009 Aug 14. Review.

14.

The benefit of long-term growth hormone (GH) replacement therapy in hypopituitary adults with GH deficiency: results of the German KIMS database.

Spielhagen C, Schwahn C, Möller K, Friedrich N, Kohlmann T, Moock J, Kołtowska-Häggström M, Nauck M, Buchfelder M, Wallaschofski H.

Growth Horm IGF Res. 2011 Feb;21(1):1-10. doi: 10.1016/j.ghir.2010.10.005. Epub 2010 Nov 19.

PMID:
21093334
15.
16.

Isolated growth hormone (GH) deficiency in adult patients: baseline clinical characteristics and responses to GH replacement in comparison with hypopituitary patients. A sub-analysis of the KIMS database.

Abs R, Mattsson AF, Bengtsson BA, Feldt-Rasmussen U, Góth MI, Koltowska-Häggström M, Monson JP, Verhelst J, Wilton P; KIMS Study Group.

Growth Horm IGF Res. 2005 Oct;15(5):349-59.

PMID:
16168692
17.

Long-term safety of recombinant human growth hormone in children.

Bell J, Parker KL, Swinford RD, Hoffman AR, Maneatis T, Lippe B.

J Clin Endocrinol Metab. 2010 Jan;95(1):167-77. doi: 10.1210/jc.2009-0178. Epub 2009 Nov 11.

PMID:
19906787
18.

Acromegaly induced by growth hormone replacement therapy.

Karges B, Pfäffle R, Boehm BO, Karges W.

Horm Res. 2004;61(4):165-9. Epub 2003 Dec 31.

PMID:
14707471
19.

Cardiovascular risk in adult patients with growth hormone (GH) deficiency and following substitution with GH--an update.

Gazzaruso C, Gola M, Karamouzis I, Giubbini R, Giustina A.

J Clin Endocrinol Metab. 2014 Jan;99(1):18-29. doi: 10.1210/jc.2013-2394. Epub 2013 Dec 20. Review.

PMID:
24217903
20.

Effects of long-term growth hormone replacement in adults with growth hormone deficiency following cure of acromegaly: a KIMS analysis.

Tritos NA, Johannsson G, Korbonits M, Miller KK, Feldt-Rasmussen U, Yuen KC, King D, Mattsson AF, Jonsson PJ, Koltowska-Haggstrom M, Klibanski A, Biller BM.

J Clin Endocrinol Metab. 2014 Jun;99(6):2018-29. doi: 10.1210/jc.2014-1013. Epub 2014 Apr 2.

PMID:
24694339

Supplemental Content

Support Center